Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

作者：Olalekan O. Oluwole, Sally W. Wade, Nathaniel Smith, Tomas Spousta, Jaeyeon Kim, Yan Zheng, Timothy Best, Markqayne Ray, Lori A. Leslie · 发表于：Transplantation and Cellular Therapy · 年份：2025 · DOI：10.1016/j.jtct.2025.01.616 · 被引用次数：2 · 研究领域：CAR-T cell therapy research、Lymphoma Diagnosis and Treatment